within Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01F_MonoclonalAntibodiesAndAntibodyDrugConjugates.L01FX16_OportuzumabMonatox;
model OportuzumabMonatox 
   extends Pharmacolibrary.Drugs.ATC.L.L01FX16;

  annotation(Documentation(
    info ="<html><body><p>Oportuzumab monatox is a recombinant fusion protein consisting of a humanized monoclonal antibody targeting EpCAM (epithelial cell adhesion molecule) fused to a truncated Pseudomonas exotoxin A. It is developed as an anti-cancer agent, specifically for the treatment of non-muscle invasive bladder cancer (NMIBC), targeting EpCAM-expressing tumor cells. The drug is not currently approved for use by regulatory agencies.</p><h4>Pharmacokinetics</h4><p>No peer-reviewed publication available reporting specific pharmacokinetic parameters for oportuzumab monatox in human populations as of the latest literature review (up to June 2024).</p><h4>References</h4><ol></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>",
    experiment(StartTime = 0, StopTime = 86400, Tolerance = 1e-09, Interval = 1)
  ));  
end OportuzumabMonatox;
